Figure 1.
Total number of lymphocytes, CD4+ T cells and CD19+ B cells in the PB.
Total number (×103 cells/µl blood) of lymphocytes, T cells and B cells in treatment-naive, IFN-β treated MS patients at baseline and fingolimod-treated MS patients during 12 months follow-up. Mean and standard error of the mean are presented. • lymphocytes; ▪ CD4+ T cells; ▴ CD19+ B cells.
Table 1.
Study population.
Figure 2.
Proportional B cell and T cell subtype changes in MS patients during fingolimod treatment.
(A) CD19+ B cell subtype proportion and (B) CD4+ T cell subtype proportion within the PB of treatment-naive, IFN-β and fingolimod-treated MS patients. Results are presented as relative values within the CD19+ B cell or CD4+ T cell population. Subtype proportions were calculated as follows: (% subtype/100)×% CD19+ or CD4+ within the total lymphocyte population. Statistically significant differences compared to 0 m are shown in bold. For B cells: naive B cells; NCSM B cells = non class-switched memory B cells; CSM B cells = class-switched memory B cells and DN B cells = double negative B cells. For T cells: nTreg = naive Treg; mTreg = memory Treg; TransTreg = transitional Treg; nTconv = naive Tconv; mTconv = memory Tconv; TransTconv = transitional Tconv.
Figure 3.
B cell expression levels of antigen presentation and costimulation molecules during fingolimod treatment.
Mean fluorescence intensity (MFI) of (A) HLA-DR/DP/DQ, (B) CD80 and (C) CD86 expression within the B cell population from fingolimod-treated MS patients during follow-up.
Figure 4.
Percentage of TFH and expression of CXCR5 and PD-1 during fingolimod treatment in MS patients.
(A.) Percentage of PB follicular helper T cells (TFH) in MS patients treated with fingolimod. Data are presented as percentage within the CD4+ T cell population. (B.) Expression of CXCR5 and (C.) expression of PD-1 within TFH cell population.